On September 1, 2026, the Food & Drug Administration (FDA) reinforced its prior conclusion that fluoropolymers used in medical devices are safe and materially different from the per- and polyfluoroalkyl substances (PFAS) that drive most regulatory, litigation and public health concerns. Specifically, FDA added a new FAQ section to its PFAS in Medical Devices webpage, which reemphasizes that fluoropolymers possess chemical and toxicological characteristics that are distinct from other PFAS, a...
Continue Reading
Sign up for FREE to read the full article and access 156K+ alternative investment headlines.